UBS Group
NEPH icon

UBS Group’s Nephros NEPH Stock Holding History

UBS Group’s Portfolio NEPH Stock Details NEPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.97K Buy
+831
New +$2.7K ﹤0.01% 9259
2025
Q4 		– Sell
-66
Closed -$312 – 10959
2025
Q3 		$312 Sell
66
-2,457
-97% -$9.65K ﹤0.01% 9742
2025
Q2 		$10.3K Buy
+2,523
New +$6.74K ﹤0.01% 8847
2025
Q1 		– Sell
-40,208
Closed -$59.1K – 10557
2024
Q4 		$59.1K Buy
40,208
+40,087
+33,130% +$61.1K ﹤0.01% 7191
2024
Q3 		$207 Sell
121
-19,237
-99% -$38K ﹤0.01% 9068
2024
Q2 		$40.8K Buy
19,358
+19,051
+6,206% +$41.1K ﹤0.01% 6846
2024
Q1 		$672 Buy
307
+296
+2,691% +$939 ﹤0.01% 8422
2023
Q4 		$38 Hold
11
– – ﹤0.01% 9020
2023
Q3 		$16 Hold
11
– – ﹤0.01% 9160
2023
Q2 		$17 Sell
11
-226
-95% -$334 ﹤0.01% 8701
2023
Q1 		$254 Sell
237
-10,294
-98% -$11.8K ﹤0.01% 9118
2022
Q4 		$12.2K Sell
10,531
-1,343
-11% -$1.43K ﹤0.01% 8307
2022
Q3 		$11K Buy
11,874
+11,348
+2,157% +$16K ﹤0.01% 8313
2022
Q2 		$1K Buy
526
+515
+4,682% +$1.39K ﹤0.01% 9916
2022
Q1 		$0 Hold
11
– – ﹤0.01% 10676
2021
Q4 		$0 Hold
11
– – ﹤0.01% 10545
2021
Q3 		$0 Sell
11
-16
-59% -$139 ﹤0.01% 9884
2021
Q2 		$0 Sell
27
-316
-92% -$2.64K ﹤0.01% 9658
2021
Q1 		$2K Buy
343
+61
+22% +$481 ﹤0.01% 8628
2020
Q4 		$2K Buy
282
+271
+2,464% +$1.83K ﹤0.01% 8107
2020
Q3 		$0 Sell
11
-10
-48% -$73 ﹤0.01% 8265
2020
Q2 		$0 Sell
21
-471
-96% -$3.73K ﹤0.01% 8214
2020
Q1 		$3K Sell
492
-110
-18% -$934 ﹤0.01% 7503
2019
Q4 		$6K Buy
602
+581
+2,767% +$5.17K ﹤0.01% 7520
2019
Q3 		$0 Buy
+21
New +$154 ﹤0.01% 8159

Other funds holding NEPH

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CC
Cornerstone Capital Palo Alto, California $1.12B AUM 28.84% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
NA
Navellier & Associates Reno, Nevada $1.26B AUM 95.39% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group's NEPH Position: Q2 2026 in Review

UBS Group opened a new position in Nephros (NEPH) in Q2 2026: 831 shares worth $2.97K. The stake represents ﹤0.01% of the portfolio and ranks #9259 among its holdings. This is a return to the name: UBS Group previously reported a position in NEPH as recently as Q3 2025.

UBS Group first reported a position in NEPH in Q3 2019 and has held it in 25 quarters since. The position peaked at $59.1K in Q4 2024. 29 funds tracked by Wall St. Rank hold NEPH as of Q2 2026.

  • UBS Group held 831 shares of Nephros worth $2.97K as of Q2 2026.
  • Nephros was a new UBS Group position in Q2 2026.
  • Nephros made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9259 holding.
  • UBS Group first reported a position in Nephros in Q3 2019 and has held it in 25 quarters since.
  • UBS Group's Nephros position peaked at $59.1K in Q4 2024.
  • 29 funds tracked by Wall St. Rank held Nephros as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.